Candidate Compounds Covid19
(Unterschied zwischen Versionen)
| Zeile 2: | Zeile 2: | ||
current items will be put into the subsections. | current items will be put into the subsections. | ||
| − | |||
| − | |||
| − | *[[reviews on covid drug development]] | + | *[[reviews on covid drug development]] |
*[[scouting ideas]] | *[[scouting ideas]] | ||
*[[Patients on biologicals]] | *[[Patients on biologicals]] | ||
*[[HMGB1, RAGE]] | *[[HMGB1, RAGE]] | ||
| − | *[[pre-Interleukin 6]] | + | *[[pre-Interleukin 6]] |
*[[post-Interleukin 6]] | *[[post-Interleukin 6]] | ||
*[[pre-TNFalpha]] | *[[pre-TNFalpha]] | ||
| Zeile 18: | Zeile 16: | ||
*[[pre-Interleukin 1]] | *[[pre-Interleukin 1]] | ||
*[[post-Interleukin 1]] | *[[post-Interleukin 1]] | ||
| − | *[[Inflammasome]] | + | *[[Inflammasome]] ''colchicine'' |
*[[other anti-inflammatory]] | *[[other anti-inflammatory]] | ||
*[[NK-kappaB]] | *[[NK-kappaB]] | ||
| Zeile 36: | Zeile 34: | ||
*[[other single compounds]] | *[[other single compounds]] | ||
*[[Retargeted single compounds]] | *[[Retargeted single compounds]] | ||
| − | *[[Hydroxychloroquine]] | + | *[[Hydroxychloroquine]] |
* | * | ||
| − | + | *[[Target ACE2, Spike protein]] | |
| + | *[[Target TMPRSS2, Spike protein]] ''any other covid targed herein'' | ||
*[[other antiviral compounds]] | *[[other antiviral compounds]] | ||
*[[AV Remdesivir]] | *[[AV Remdesivir]] | ||
*[[AV Lopinavir]] | *[[AV Lopinavir]] | ||
*[[AV Ivermectin]] | *[[AV Ivermectin]] | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| Zeile 54: | Zeile 47: | ||
*[[Vitamin D]] | *[[Vitamin D]] | ||
| − | |||
| − | |||
*[[Anorganic nutrients Magnesium]] | *[[Anorganic nutrients Magnesium]] | ||
*[[Anorganic nutrients Selenium]] | *[[Anorganic nutrients Selenium]] | ||
| Zeile 70: | Zeile 61: | ||
*[[RSP - On RAS drugs]] | *[[RSP - On RAS drugs]] | ||
| − | *[[Reconvalescent blood products, Passive vaccine]] | + | *[[Reconvalescent blood products, Passive vaccine]] |
*[[Plasmapheresis]] | *[[Plasmapheresis]] | ||
| Zeile 76: | Zeile 67: | ||
*[[Radiation therapy]] | *[[Radiation therapy]] | ||
*[[Phototherapy]] | *[[Phototherapy]] | ||
| − | *[[Active vaccine]] | + | *[[Active vaccine]] |
| − | + | -rest- | |
{{tp|p=32229705|t=2020. Geroprotective and senoremediative strategies to reduce the comorbidity, infection rates, severity, and lethality in gerophilic and gerolavic infections |pdf=|usr=}} | {{tp|p=32229705|t=2020. Geroprotective and senoremediative strategies to reduce the comorbidity, infection rates, severity, and lethality in gerophilic and gerolavic infections |pdf=|usr=}} | ||
| − | |||
{{tp|p=32276453|t=2020. Exploring the Relevance of Senotherapeutics for the Current SARS-CoV-2 Emergency and Similar Future Global Health Threats |pdf=|usr=}} | {{tp|p=32276453|t=2020. Exploring the Relevance of Senotherapeutics for the Current SARS-CoV-2 Emergency and Similar Future Global Health Threats |pdf=|usr=}} | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
{{tp|p=32325124|t=ä. Vaporization, bioactive formulations and a marine natural product: different perspectives on antivirals |pdf=|usr=}} | {{tp|p=32325124|t=ä. Vaporization, bioactive formulations and a marine natural product: different perspectives on antivirals |pdf=|usr=}} | ||
| − | |||
{{tp|p=32312129|t=2020. The role of additive manufacturing and antimicrobial polymers in the COVID-19 pandemic |pdf=|usr=}} | {{tp|p=32312129|t=2020. The role of additive manufacturing and antimicrobial polymers in the COVID-19 pandemic |pdf=|usr=}} | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
{{tp|p=32336674|t=ä. COVID-19 Emergency Responders in FDA?s Center for Drug Evaluation and Research |pdf=|usr=}} | {{tp|p=32336674|t=ä. COVID-19 Emergency Responders in FDA?s Center for Drug Evaluation and Research |pdf=|usr=}} | ||
| − | |||
| − | |||
| − | |||
| − | |||
{{tp|p=32356251|t=ä. Medical Toxicology and COVID-19: Our Role in a Pandemic |pdf=|usr=}} | {{tp|p=32356251|t=ä. Medical Toxicology and COVID-19: Our Role in a Pandemic |pdf=|usr=}} | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
{{tp|p=32243778|t=2020. Ensuring global access to COVID-19 vaccines |pdf=|usr=}} | {{tp|p=32243778|t=2020. Ensuring global access to COVID-19 vaccines |pdf=|usr=}} | ||
{{tp|p=32247324|t=2020. Global coalition to accelerate COVID-19 clinical research in resource-limited settings |pdf=|usr=}} | {{tp|p=32247324|t=2020. Global coalition to accelerate COVID-19 clinical research in resource-limited settings |pdf=|usr=}} | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
{{tp|p=32272857|t=2020. Role of Tissue Engineering in COVID-19 and Future Viral Outbreaks |pdf=|usr=}} | {{tp|p=32272857|t=2020. Role of Tissue Engineering in COVID-19 and Future Viral Outbreaks |pdf=|usr=}} | ||
| − | |||
{{tp|p=C7190525|t=2020. Adjunct Immunotherapies for the Management of Severely Ill COVID-19 Patients |pdf=|usr=}} | {{tp|p=C7190525|t=2020. Adjunct Immunotherapies for the Management of Severely Ill COVID-19 Patients |pdf=|usr=}} | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
{{tp|p=32129977|t=2020. Cell-Membrane-Mimicking Nanodecoys against Infectious Diseases |pdf=|usr=}} | {{tp|p=32129977|t=2020. Cell-Membrane-Mimicking Nanodecoys against Infectious Diseases |pdf=|usr=}} | ||
{{tp|p=29115746|t=2018. Progress Toward the Clinical Translation of Bioinspired Peptide and Protein Assemblies |pdf=|usr=}} | {{tp|p=29115746|t=2018. Progress Toward the Clinical Translation of Bioinspired Peptide and Protein Assemblies |pdf=|usr=}} | ||
{{tp|p=29717819|t=2018. Recent Advances in the Development of Antimicrobial Nanoparticles for Combating Resistant Pathogens |pdf=|usr=}} | {{tp|p=29717819|t=2018. Recent Advances in the Development of Antimicrobial Nanoparticles for Combating Resistant Pathogens |pdf=|usr=}} | ||
| − | |||
| − | |||
| − | |||
| − | |||
{{tp|p=C7194243|t=ä. Coronavirus Disease 2019 (COVID-19) Spread and Pharmacovigilance Implications: Expert Opinion |pdf=|usr=}} | {{tp|p=C7194243|t=ä. Coronavirus Disease 2019 (COVID-19) Spread and Pharmacovigilance Implications: Expert Opinion |pdf=|usr=}} | ||
{{tp|p=32383008|t=ä. The Role of Pharmacovigilance and ISoP During the Global COVID-19 Pandemic |pdf=|usr=}} | {{tp|p=32383008|t=ä. The Role of Pharmacovigilance and ISoP During the Global COVID-19 Pandemic |pdf=|usr=}} | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
{{tp|p=32380052|t=2020. Granulocyte-targeted therapies for airway diseases |pdf=|usr=}} | {{tp|p=32380052|t=2020. Granulocyte-targeted therapies for airway diseases |pdf=|usr=}} | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
{{tp|p=32452420|t=2020. Antiviral activity of lycorine against Zika virus in vivo and in vitro |pdf=|usr=}} | {{tp|p=32452420|t=2020. Antiviral activity of lycorine against Zika virus in vivo and in vitro |pdf=|usr=}} | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
Version vom 21. Juni 2020, 16:47 Uhr
coviki.org collects the really good Ideas and the scientific Record on Covid-19 Virus.
current items will be put into the subsections.
- Patients on biologicals
- HMGB1, RAGE
- pre-Interleukin 6
- post-Interleukin 6
- pre-TNFalpha
- post-TNFalpha
- pre-Interleukin 17
- post-Interleukin 17
- pre-Interleukin 1
- post-Interleukin 1
- Inflammasome colchicine
- other anti-inflammatory
- NK-kappaB
- STAT 3
- JAK Janus Kinase
- Corticosteroids
- Cytokine absorbers
- Target Complement system
- Target Extracellular traps
- Anticoagulant in covid19
- Antioxidants
- Stem cells
- MDSC cells
- Interferons
- other single compounds
- Retargeted single compounds
- Hydroxychloroquine
- Target ACE2, Spike protein
- Target TMPRSS2, Spike protein any other covid targed herein
- other antiviral compounds
- AV Remdesivir
- AV Lopinavir
- AV Ivermectin
- Vitamin D
- Anorganic nutrients Magnesium
- Anorganic nutrients Selenium
- Anorganic nutrients Zinc
- Nutrition, general
- Exercise, Vibration
- Immunodeviation e.g. by adjuvants or other vaccinations
- Radiation therapy
- Phototherapy
- Active vaccine
-rest-
32229705 2020. Geroprotective and senoremediative strategies to reduce the comorbidity, infection rates, severity, and lethality in gerophilic and gerolavic infections
32276453 2020. Exploring the Relevance of Senotherapeutics for the Current SARS-CoV-2 Emergency and Similar Future Global Health Threats
32325124 ä. Vaporization, bioactive formulations and a marine natural product: different perspectives on antivirals
32312129 2020. The role of additive manufacturing and antimicrobial polymers in the COVID-19 pandemic
32336674 ä. COVID-19 Emergency Responders in FDA?s Center for Drug Evaluation and Research
32356251 ä. Medical Toxicology and COVID-19: Our Role in a Pandemic
32243778 2020. Ensuring global access to COVID-19 vaccines
32247324 2020. Global coalition to accelerate COVID-19 clinical research in resource-limited settings
32272857 2020. Role of Tissue Engineering in COVID-19 and Future Viral Outbreaks
C7190525 2020. Adjunct Immunotherapies for the Management of Severely Ill COVID-19 Patients
32129977 2020. Cell-Membrane-Mimicking Nanodecoys against Infectious Diseases
29115746 2018. Progress Toward the Clinical Translation of Bioinspired Peptide and Protein Assemblies
29717819 2018. Recent Advances in the Development of Antimicrobial Nanoparticles for Combating Resistant Pathogens
C7194243 ä. Coronavirus Disease 2019 (COVID-19) Spread and Pharmacovigilance Implications: Expert Opinion
32383008 ä. The Role of Pharmacovigilance and ISoP During the Global COVID-19 Pandemic
32380052 2020. Granulocyte-targeted therapies for airway diseases
32452420 2020. Antiviral activity of lycorine against Zika virus in vivo and in vitro
